Literature DB >> 35584840

Acute leukaemia: no reason to panic.

Eleni E Ladikou1, Iona Ashworth2, Dale Seviar3, Timothy Chevassut2.   

Abstract

Acute leukaemia is characterised by uncontrolled expansion of immature leukocytes, either myeloid or lymphoid progenitors, leading to acute myeloid leukaemia (AML) and acute lymphoid leukaemia (ALL), respectively. If left untreated, it is life-threatening and can lead to death within weeks. When acute leukaemia is suspected, urgent haematology input should be sought. Appropriate investigations are needed promptly to confirm diagnosis and start treatment. A multidisciplinary approach is vital to ensure appropriate management. © Royal College of Physicians 2022. All rights reserved.

Entities:  

Keywords:  ALL; AML; haematology; leukaemia

Mesh:

Year:  2022        PMID: 35584840      PMCID: PMC9135077          DOI: 10.7861/clinmed.2022-0149

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   5.410


  12 in total

1.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.

Authors:  Hagop Kantarjian; Susan O'brien; Jorge Cortes; Francis Giles; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; William Wierda; Sherry Pierce; Jianqin Shan; Elihu Estey
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

2.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Authors:  Christian Thiede; Sina Koch; Eva Creutzig; Christine Steudel; Thomas Illmer; Markus Schaich; Gerhard Ehninger
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

Review 3.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

4.  Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

Authors:  Thomas Büchner; Wolfgang E Berdel; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger; Carsten Müller-Tidow; Jan Braess; Karsten Spiekermann; Joachim Kienast; Peter Staib; Andreas Grüneisen; Wolfgang Kern; Albrecht Reichle; Georg Maschmeyer; Carlo Aul; Eva Lengfelder; Maria-Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

Review 5.  Acute myeloid leukaemia in adults.

Authors:  Felicetto Ferrara; Charles A Schiffer
Journal:  Lancet       Date:  2013-02-09       Impact factor: 79.321

Review 6.  An update of current treatments for adult acute myeloid leukemia.

Authors:  Hervé Dombret; Claude Gardin
Journal:  Blood       Date:  2015-12-10       Impact factor: 22.113

Review 7.  Current findings for recurring mutations in acute myeloid leukemia.

Authors:  Shinichiro Takahashi
Journal:  J Hematol Oncol       Date:  2011-09-14       Impact factor: 17.388

8.  Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.

Authors:  Lynn Quek; Georg W Otto; Catherine Garnett; Ludovic Lhermitte; Dimitris Karamitros; Bilyana Stoilova; I-Jun Lau; Jessica Doondeea; Batchimeg Usukhbayar; Alison Kennedy; Marlen Metzner; Nicolas Goardon; Adam Ivey; Christopher Allen; Rosemary Gale; Benjamin Davies; Alexander Sternberg; Sally Killick; Hannah Hunter; Paul Cahalin; Andrew Price; Andrew Carr; Mike Griffiths; Paul Virgo; Stephen Mackinnon; David Grimwade; Sylvie Freeman; Nigel Russell; Charles Craddock; Adam Mead; Andrew Peniket; Catherine Porcher; Paresh Vyas
Journal:  J Exp Med       Date:  2016-07-04       Impact factor: 14.307

Review 9.  'Acute myeloid leukemia: a comprehensive review and 2016 update'.

Authors:  I De Kouchkovsky; M Abdul-Hay
Journal:  Blood Cancer J       Date:  2016-07-01       Impact factor: 11.037

Review 10.  Environmental Risk Factors for Childhood Acute Lymphoblastic Leukemia: An Umbrella Review.

Authors:  Felix M Onyije; Ann Olsson; Dan Baaken; Friederike Erdmann; Martin Stanulla; Daniel Wollschläger; Joachim Schüz
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.